RECURSION PHARMACEUTICALS, INC. Operating Lease Cost
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Operating Lease Cost of $16.09 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2024-12-31 was $3.48M, a 65.37% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2024-09-30 was $3.02M, a 49.21% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2024-06-30 was $3.11M, a 53.91% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2024-03-31 was $2.47M, a 23.72% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating lease, cost for fiscal 2025 was $16.09M, a 33.18% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. operating lease, cost for fiscal 2024 was $12.08M, a 48.31% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. operating lease, cost for fiscal 2023 was $8.14M, a 4.50% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. operating lease, cost for fiscal 2022 was $7.79M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $16.09M 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $6.50M derived: sum of 2 quarters · filed 2026-02-25 | $9.61M derived: sum of 3 quarters · filed 2026-02-25 | $12.08M 10-K · filed 2026-02-25 |
| 2024-09-30 | $3.02M 10-Q · filed 2024-11-06 | $6.13M derived: sum of 2 quarters · filed 2024-11-06 | $8.60M 10-Q · filed 2024-11-06 | $10.70M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $3.11M 10-Q · filed 2024-08-08 | $5.58M 10-Q · filed 2024-08-08 | $7.68M derived: sum of 3 quarters · filed 2026-02-25 | $9.71M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $2.47M 10-Q · filed 2024-05-09 | $4.57M derived: sum of 2 quarters · filed 2026-02-25 | $6.60M derived: sum of 3 quarters · filed 2026-02-25 | $8.62M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.13M derived: sum of 2 quarters · filed 2026-02-25 | $6.15M derived: sum of 3 quarters · filed 2026-02-25 | $8.14M 10-K · filed 2026-02-25 |
| 2023-09-30 | $2.02M 10-Q · filed 2024-11-06 | $4.04M derived: sum of 2 quarters · filed 2024-11-06 | $6.04M 10-Q · filed 2024-11-06 | $8.03M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $2.02M 10-Q · filed 2024-08-08 | $4.02M 10-Q · filed 2024-08-08 | $6.01M derived: sum of 3 quarters · filed 2025-02-28 | $8.03M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $2.00M 10-Q · filed 2024-05-09 | $3.99M derived: sum of 2 quarters · filed 2025-02-28 | $6.01M derived: sum of 3 quarters · filed 2025-02-28 | $7.96M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $4.01M derived: sum of 2 quarters · filed 2025-02-28 | $5.97M derived: sum of 3 quarters · filed 2025-02-28 | $7.79M 10-K · filed 2025-02-28 |
| 2022-09-30 | $2.02M 10-Q · filed 2023-11-09 | $3.97M derived: sum of 2 quarters · filed 2023-11-09 | $5.80M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $1.96M 10-Q · filed 2023-08-08 | $3.78M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $1.83M 10-Q · filed 2023-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |